Please assess the completion status of the following clinical trial:

Trial Title: Partial Left Ventricular Support in Advanced Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with ischaemic or dilated cardiomyopathy aged 18 to 80 years.~* Symptoms categorised by INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) at level 3-6 despite optimal tolerated medical therapy. Practically this includes patients who are in hospital or managing at home with substantial dependence on hospital care.~* Peak VO2 \<15ml/kg/min with respiratory exchange ratio\>1 on cardiopulmonary exercise testing OR a 6-minute walking distance \<300m OR inability to perform an exercise test due to the severity of heart failure.~* Informed consent obtained prior to entering the study.~Exclusion Criteria:~* Cause of heart failure due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or active myocarditis~* Body surface area \<1.2M2 or \>2.3M2, or body mass index \>32 kg/M2.~* Severe chronic obstructive pulmonary disease as evidenced by forced expiratory volume in 1 second \<50% of predicted.~* History of pulmonary hypertension with maintained pulmonary vascular resistance measured \> 4 Wood units or transpulmonary gradient \>14mmHg.~* Pregnancy.~* Evidence of intrinsic hepatic disease defined as liver enzyme levels \> 5 times the upper limit of normal within 4 days before enrolment, severe liver dysfunction, cirrhosis or portal hypertension.~* Occurrence of stroke within 90 days before enrolment.~* Impairment of cognitive function or presence of any form of irreversible dementia.~* Recent history of psychiatric disease (including severe drug or alcohol abuse) that is likely to impair compliance with the study protocol.~* Platelet count \<50 x103mm3 within 24 hours before enrolment.~* Creatinine clearance \< 30ml/min.~* High probability of non-compliance.~* The patient is deemed unsuitable by the clinical team for other reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Synergy (Type: None): Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
- Control (Type: None): Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).